Update on the clinical development of cangrelor

References

• Story RF, Newby LJ, Heptinstall S. Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets12(7), 443–447 (2001).
   PubMed Web of Science ®Google Scholar
• Gachet C. ADP receptors of platelets and their inhibition. Thromb. Haemost.86(1), 222–232 (2001).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ. J.74(4), 597–607 (2010).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med.352(12), 1179–1189 (2005).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366(9497), 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA288(19), 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N. Engl. J. Med.339(23), 1665–1671 (1998).
   PubMed Web of Science ®Google Scholar
• Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med.334(17), 1084–1089 (1996).
   PubMed Web of Science ®Google Scholar
• Urban P, Macaya C, Rupprecht HJ et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation98(20), 2126–2132 (1998).
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Legrand V, Boland J et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation98(16), 1596–1603 (1998).
   Google Scholar
• Angiolillo DJ, Bhatt DL, Gurbel PA Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am. J. Cardiol.103, 40A–51A (2009).
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH; CLASSICS Investigators. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation102(6), 624–629 (2000).
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Managament of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol.50(7), E1–E157 (2007).
   Google Scholar
• Kushner FG, Hand M, Smith SC et al. Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update). J. Am. Coll. Cardiol.54(23), 2205–2241 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Sabaté M et al. Impact of platelet reactivity on cardiovascular outcomes in patients with Type 2 diabetes mellitus and coronary artery disease. J. Am. Coll. Cardiol.50(16), 1541–1547 (2007).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb. Haemost.102(1), 7–14 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Ferreiro JL. Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions. Rev. Esp. Cardiol.63(1), 60–76 (2010).
   PubMed Web of Science ®Google Scholar
• Heestermans AA, van Werkum JW, Taubert D et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb. Res.122(6), 776–781 (2008).
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH et al. ; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.357(20), 2015–2021 (2007).
   Google Scholar
• Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med.361(11), 1045–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Ueno M, Angiolillo DJ. Cangrelor: a review on its mechanism of action and clinical development. Expert Rev. Cardiovasc. Ther.7(10), 1195–1201 (2009).
   PubMedGoogle Scholar
• Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am. Heart J.156(Suppl. 2), S10–S15 (2008).
   PubMed Web of Science ®Google Scholar
• Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J. Clin. Invest.113(3), 340–345 (2004).
   PubMed Web of Science ®Google Scholar
• Hechler B, Vigne P, Léon C, Breittmayer JP, Gachet C, Frelin C. ATP derivative are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol. Pharmacol.53(4), 727–733 (1998).
   PubMed Web of Science ®Google Scholar
• Ingall AH, Dixon J, Bailey A et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J. Med. Chem.42(2), 213–220 (1999).
   PubMed Web of Science ®Google Scholar
• Kunapuli SP, Ding Z, Dorsam RT et al. ADP receptors-targets for developing antithrombotic agents. Curr. Pharm. Des.9(28), 2303–2316 (2003).
   PubMed Web of Science ®Google Scholar
• Humphries RG, Robertson MJ, Leff P. A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends Pharmacol. Sci.16(6), 179–181 (1995).
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost.31(2), 195–204 (2005).
   PubMed Web of Science ®Google Scholar
• Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndrome. Thromb. Haemost.85(3), 401–407 (2001).
   PubMed Web of Science ®Google Scholar
• Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J. Pharmacol. Exp. Ther.295(2), 492–499 (2000).
   PubMed Web of Science ®Google Scholar
• van Gestel MA, Heemskerk JW, Slaaf DW Heijnen VV, Reneman RS, oude Egbrink MG. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler. Thromb. Vasc. Biol.23(3), 518–523 (2003).
   PubMed Web of Science ®Google Scholar
• Nassim MA, Sanderson JB, Clarke C et al. Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers. J. Am. Coll. Cardiol.33(2 Suppl. A), A255 (1999).
   Web of Science ®Google Scholar
• Javis GE, Nassim MA, Humphries RG et al. The P2Y antagonist AR-C69931MX is a more effective inhibitor of ADP-induced platelet aggregation than clopidogrel. Blood94(Suppl. 1), A22 (1999).
   Google Scholar
• Jacobsson F, Swahn E, Wallentin L Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin. Ther.24(5), 752–765 (2002).
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Ohman EM, Gibson CM et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am. Heart J.154(4), 702–709 (2007).
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Grines CL, Bittl JA et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, Phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J.151(3), 689.e1–689.e10 (2006).
   PubMed Web of Science ®Google Scholar
• Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets13(7), 407–413 (2002).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res.121(4), 527–534 (2008).
   PubMed Web of Science ®Google Scholar
• Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J. Thromb. Haemost.6(7), 1153–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Harrington RA, Stone GW, McNulty S et al. Platelet inhibition with cangrelor in patients undergoing PCI. N. Engl. J. Med.361(24), 2318–2329 (2009).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Lincoff M, Gibson M et al. Intravenous platelet blockade with cangrelor during PCI. N. Engl. J. Med.361(24), 2330–2341 (2009).
   PubMed Web of Science ®Google Scholar
• Ueno M, Rao SV, Angiolillo DJ. Elinogrel. Pharmacological principles, pre-clinical and early phase clinical testing. Future Cardiol. (2010) (In Press).
   PubMedGoogle Scholar